 The phase 2 combination trial could potentially lead to a registrational study in China in 2022 Accelerated development plan for lemzoparlimab aiming for NDA approval in China for treatment of hematologic malignancies Two U.S. c ohort expansion studies in non-Hodgkin lymphoma and advanced solid tumors on track to deliver preliminary topline results by end 2021 or early 2022 SHANGHAI and GAITHERSBURG, Md., May 18, 2021 PRNewswire -- I-Mab the Company Nasdaq: IMAB, a clinical-stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that the first patient has been dosed in an abbreviated combination clinical study NCT04202003 of lemzoparlimab also known as TJC4 with azacitidine AZA in patients with newly diagnosed Acute Myeloid Leukemia AML or Myelodysplastic Syndrome MDS in China. 